A new fructose-free, resistant-starch type IV-enriched enteral formula improves glycaemic control and cardiovascular risk biomarkers when administered for six weeks to elderly diabetic patients.
FI: 0,747
Type: Article
Artículo original
Year: 2017
Writers
Garcia, MDM; Garcia-Rodriguez, CE; Rico, M.D.; Aguilera, C.M.; Perez-Rodriguez, M; Perez-de-la-Cruz, AJ; Gil, A.
Magazine
Title: NUTRICION HOSPITALARIA
Quartile
- Q4